title: Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia.
abstract: BACKGROUND
  The percentage of myeloperoxidase (MPO)-positive blast cells is associated with prognosis in adult acute myeloid leukemia (AML), but this association is unsubstantiated in pediatric AML.
  
  
  METHODS
  We retrospectively compared cytochemical MPO results with outcome in 154 patients younger than 21 years treated on three consecutive institutional protocols for newly diagnosed AML (1987-2001). Patients with FAB M0 and M7 AML (no MPO expression) or M3 AML (100% MPO expression) and Down's syndrome were excluded.
  
  
  RESULTS
  Median MPO expression was higher in FAB M2 subtype than in other subtypes (P < 0.0001) and differed significantly across cytogenetic risk groups (P = 0.002) with highest MPO expression among those with favorable karyotypes. The percentage of MPO-positive blasts was not significantly associated with the probability of complete remission (P = 0.97), event-free survival (P = 0.72), or survival (P = 0.76) in multivariate analyses that accounted for age, FAB subtype, presenting WBC count, cytogenetic and protocol treatment risk group. In analysis limited to patients with intermediate-risk cytogenetics, higher MPO expression appeared to be associated with improved EFS (P = 0.06) but was not associated with remission induction rate (P = 0.16) or overall survival (P = 0.38).
  
  
  CONCLUSIONS
  The percentage of MPO-positive blast cells is related to FAB subtype in pediatric AML but has limited prognostic relevance.
authors.affiliation: Department of Hematology-Oncology, St. Jude Children's Research Hospital, and the University of Tennessee College of Medicine, Memphis, Tennessee, USA.
authors.forename: Jessica R
authors.initials: JR
authors.lastname: Roberson
authors.forename: Mihaela
authors.initials: M
authors.lastname: Onciu
authors.forename: Stanley
authors.initials: S
authors.lastname: Pounds
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Rubnitz
authors.forename: Ching-Hon
authors.initials: CH
authors.lastname: Pui
authors.forename: Bassem I
authors.initials: BI
authors.lastname: Razzouk
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D015415:Biomarkers; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D053208:Kaplan-Meier Estimate; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000097:blood* / Q000145:classification / Q000235:genetics / Q000401:mortality; D008297:Male; D022423:Myeloid Cells / Q000201:enzymology*; D014411:Neoplastic Stem Cells / Q000201:enzymology*; D009195:Peroxidase / Q000097:blood*; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk; D016019:Survival Analysis
chemical_list: D015415:Biomarkers; D009195:Peroxidase